M-M-R II Vaccine Description
Merck's M-M-R II vaccine is also known as Measles, Mumps, and Rubella Virus Vaccine Live, is a live virus MMR vaccine, containing weakened forms of measles virus, mumps virus, and rubella virus. M-M-R II works by helping the immune system protect itself from these viruses.
The active ingredients include weakened forms of the measles, mumps, and rubella (MMR) viruses. The inactive ingredients include sorbitol, sucrose, hydrolyzed gelatin, recombinant human albumin, fetal bovine serum, other buffer and media ingredients, neomycin.
Clinical studies of 284 triple-seronegative children 11 months to 7 years of age demonstrated that M-M-R®II is highly immunogenic and generally well-tolerated. In these studies, a single injection of the vaccine-induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible persons.
However, a small percentage (1%-5%) of vaccinees may fail to seroconvert after the primary dose. The most common side effect of vaccination with M-M-R II is pain at the site of the shot for a short time. Other side effects may include Fever and Rash.
The MMR vaccine was developed by Maurice Hilleman and was licensed for use by Merck in 1971.
M-M-R II Vaccine Indication
It is indicated for simultaneous vaccination against measles (rubeola), mumps, and rubella (German measles). This vaccine is usually given to people 1-year-old or older.
M-M-R II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic or anaphylactoid reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; primary or acquired immunodeficiency conditions; family history of congenital or hereditary immunodeficiency or receiving immunosuppressive therapy; an active febrile illness; or those who are pregnant. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for 3 months following vaccination.
M-M-R II Vaccine Dosage
The ACIP committee recommends administration of the 1st dose of M-M-R II at 12 to 15 months of age and administration of the second dose of M-M-R®II at 4 to 6 years of age.
The M-M-R II vaccine is given as a shot administered subcutaneously, preferably into the outer aspect of the arm. The dose of the vaccine is the same for everyone. If your child gets the shot when he or she is one year old or older, a second dose is recommended.
Often, the 2nd dose is given right before the child goes to elementary school (4 to 6 years of age). If your child is less than one year old when he or she first gets the shot, a second dose should be given when they are 12 to 15 months old.
Then, a 3rd shot should be given between 4 and 6 years of age.
M-M-R II Vaccine News
September 15, 2020 - All travelers to Africa, including infants and pre-school aged children, should be fully vaccinated against measles, according to CDC immunization schedules.
September 3, 2020 - Global trial to test whether the MMR vaccine protects front-line health-care workers against COVID-19.
September 3, 2020 - An international research network announced it is launching the CROWN CORONATION phase 3 clinical trial to evaluate whether the vaccine for measles, mumps, and rubella (MMR) can protect front-line health-care workers against infection from SARS-CoV-2, the virus that causes COVID-19.
September 1, 2020 - A study was published in The Lancet: Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis.
June 19, 2020 - A study published in the journal mBio suggests that the measles, mumps, rubella (MMR) vaccine could reduce the inflammation associated with COVID-19 disease. These researchers stated: 'There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by ... inducing “trained” nonspecific innate immune cells for improved host responses against subsequent infections.'
May 18, 2020 - Routine vaccinations for young children in the U.S. fell during the first half of this year as more Americans skipped routine doctor visits due to the coronavirus pandemic, according to a report published Monday by the Centers for Disease Control and Prevention.
May 3, 2020 - The report MMR Vaccine Link to COVID-19: Fewer Deaths and Milder Cases from SARS-CoV-2 in Measles-Rubella Vaccinated Populations reveals that the MMR vaccine launched in 1971 (49 years ago) could explain why those 49 and under are much less likely to have bad outcomes from COVID-19 compared to those 50 and over, according to report co-contributor Dr. Larry P. Tilley, an Advisory Board Member of World Organization.
April 28, 2020 – Public health officials in Mexico have identified a measles virus outbreak in various states in Mexico.
April 27, 2020 – A new review of the existing evidence on the safety and effectiveness of measles-related vaccines supports their continued use for mass immunization around the world.
M-M-R II Vaccine Clinical Trials
Clinical Trial NCT01702428: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age.
ClinicalTrial NCT04333732: CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION (CROWN CORONA). CROWN CORONATION is an international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers. Randomization will be stratified by age (<50 and ≥50) and site. Participants will be healthcare workers at risk of contracting SARS-CoV-2.